Verona Pharma Plc Stock London S.E.
Equities
GB00B06GSH43
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
Sales 2024 * | 17.18M 21.41M | Sales 2025 * | 103M 129M | Capitalization | 1.02B 1.27B |
---|---|---|---|---|---|
Net income 2024 * | -83M -103M | Net income 2025 * | -38M -47.35M | EV / Sales 2024 * | 48.4 x |
Net cash position 2024 * | 184M 229M | Net cash position 2025 * | 146M 182M | EV / Sales 2025 * | 8.41 x |
P/E ratio 2024 * |
-32.3
x | P/E ratio 2025 * |
-80.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma Plc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 105B | |
+3.22% | 97.5B | |
+1.86% | 22.19B | |
-16.53% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.09% | 14.52B | |
+5.47% | 14.09B | |
+28.85% | 10.99B |